Winnow Wealth LLC Acquires New Stake in Insulet Corporation $PODD

Winnow Wealth LLC acquired a new stake in Insulet Corporation (NASDAQ:PODD) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 2,789 shares of the medical instruments supplier’s stock, valued at approximately $862,000.

A number of other institutional investors have also recently made changes to their positions in the business. Sage Mountain Advisors LLC raised its position in Insulet by 4.6% in the 3rd quarter. Sage Mountain Advisors LLC now owns 743 shares of the medical instruments supplier’s stock valued at $229,000 after purchasing an additional 33 shares in the last quarter. Curi Capital LLC raised its holdings in Insulet by 0.8% in the second quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock valued at $1,365,000 after acquiring an additional 36 shares in the last quarter. Evelyn Partners Investment Management Services Ltd raised its holdings in Insulet by 28.7% in the second quarter. Evelyn Partners Investment Management Services Ltd now owns 175 shares of the medical instruments supplier’s stock valued at $55,000 after acquiring an additional 39 shares in the last quarter. Camarda Financial Advisors LLC lifted its stake in Insulet by 0.5% in the second quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock worth $2,304,000 after acquiring an additional 40 shares during the last quarter. Finally, PDS Planning Inc grew its holdings in Insulet by 5.1% during the 3rd quarter. PDS Planning Inc now owns 821 shares of the medical instruments supplier’s stock worth $253,000 after acquiring an additional 40 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research firms have recently commented on PODD. Jefferies Financial Group increased their price objective on Insulet from $375.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, November 6th. TD Cowen lowered shares of Insulet from a “buy” rating to a “hold” rating and set a $294.00 price target on the stock. in a research note on Monday. Zacks Research cut shares of Insulet from a “strong-buy” rating to a “hold” rating in a report on Monday, January 5th. The Goldman Sachs Group restated a “buy” rating and issued a $365.00 target price on shares of Insulet in a report on Friday, January 9th. Finally, Royal Bank Of Canada increased their target price on shares of Insulet from $370.00 to $380.00 and gave the company an “outperform” rating in a research report on Friday, November 21st. Twenty investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $375.05.

Insulet Stock Up 0.3%

Shares of NASDAQ:PODD opened at $255.81 on Friday. Insulet Corporation has a fifty-two week low of $230.05 and a fifty-two week high of $354.88. The company has a quick ratio of 2.18, a current ratio of 2.87 and a debt-to-equity ratio of 0.68. The firm’s 50-day simple moving average is $291.55 and its 200-day simple moving average is $308.99. The company has a market cap of $18.00 billion, a price-to-earnings ratio of 74.15, a PEG ratio of 1.42 and a beta of 1.40.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. Insulet had a net margin of 9.76% and a return on equity of 24.36%. The firm had revenue of $521.70 million during the quarter, compared to the consensus estimate of $678.70 million. During the same quarter last year, the firm earned $1.08 earnings per share. The firm’s revenue was up 29.9% compared to the same quarter last year. As a group, equities research analysts predict that Insulet Corporation will post 3.92 earnings per share for the current year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.